Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-02-28
2000-08-15
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
544283, A61K 31505, C07D23972
Patent
active
061037281
ABSTRACT:
Molecules that are capable of modulating tyrosine signal transduction to prevent and treat cell proliferative disorders or cell differentiation disorders with particular tyrosine kinases by inhibiting one or more abnormal tyrosine kinase activities. These compounds have the structural formula ##STR1## wherein R1-R10 are disclosed in the specification. The specification also provides pharmaceutical compositions and methods for inhibiting cell proliferation or differentiation and related disorders.
REFERENCES:
patent: Re36256 (1999-07-01), Spada et al.
patent: 3266990 (1966-08-01), Lutz et al.
patent: 3800039 (1974-03-01), Marquis et al.
patent: 4343940 (1982-08-01), Kreighbaum et al.
patent: 4447608 (1984-05-01), Jones et al.
patent: 4757072 (1988-07-01), Kabbe et al.
patent: 4966849 (1990-10-01), Vallee et al.
patent: 5217999 (1993-06-01), Levitzki et al.
patent: 5302606 (1994-04-01), Spada et al.
patent: 5316553 (1994-05-01), Kaul et al.
patent: 5330992 (1994-07-01), Eissenstat et al.
patent: 5721237 (1998-02-01), Myers et al.
Aaronson, "Growth Factors and Cancer," Science 254:1146-1153 (1991).
Arvidsson et al., "Tyr-716 in the Platelet-Derived Growth Factor .beta.-Receptor Kinase Insert is Involved in GRB2 Binding and Ras Activation," Molecular and Cellular Biology 14:6715-6726 (1994).
Barker et al., "In vitro activity of non-glutamate containing quinazoline-based thymidylate synthase inhibitors," Proceedings of the American Association for Cancer Research 32:327 at abstract No. 1939 (1991).
Baserga, "The Insulin-like Growth Factor I Receptor: A Key to Tumor Growth ?" Cancer Research 55:249-252 (1995).
Bertino, "Toward Improved Selectivity in Cancer Chemotherapy: The Richard and Hinda Rosenthal Foundation Award Lecture," Cancer Research 39:293-304 (1979).
Bisbee, "Scatter factor/hepatocyte growth factor gene deletion leads to death in knockout mice," BioWorld Today 24:2 (Feb. 1995).
Budesinsky et al., "Alkoxyquinazolines," Chemical Abstracts 86(28):569 at abstract No. 140078g (1977).
Carraway and Cantley, "A Neu Acquaintance for ErbB3 and ErbB4: A Role for Receptor Heterodimerization in Growth Signaling," Cell 78:5-8 (1994).
Carraway et al., "The erbB3 Gene Product Is a Receptor for Heregulin," J. Biol. Chem. 269:14303-14306 (1994).
Claesson-Welsh, "Signal Transduction by the PDGF Receptors," Progress in Growth Factor Research 5:37-54 (1994).
Cullen et al., "Insulinlike Growth Factors in Human Malignancy," Cancer Investigation 9:443-454 (1991).
Curtin et al., "Inhibition of the growth of human hepatocellular carcinoma in vitro and in athymic mice by a quinazoline inhibitor of thymidylate synthase, CD3717," Br. J. Cancer 53:361-368 (1986).
Dati et al., "Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells," Oncogene 5:1001-1006 (1990).
De Vries et al., "The fms-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," Science 255:989-991 (1992).
Decker and Lohmann-Matthes, "A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity," J. Immunol. Methods 15:61-69 (1988).
Di Renzo et al., "Expression of the Met/Hepatocyte Growth Factor Receptor in Human Pancreatic Cancer," Cancer Research 55:1129-1138 (1995).
Di Renzo et al., "Expression of the Met/HGF receptor in normal and neoplastic human tissues," Oncogene 6:1997-23003 (1991).
Dougall et al., "The neu-oncogene: signal transduction pathways, transformation mechanisms evolving therapies," Oncogene 9:2109-2123 (1994).
Elderfield and Serlin, "The Acid Catalyzed Cleavage of 4-Quinazolylmalonic Ester and Related Compounds to 4-Quinazolone," J. Org. Chem. 16:1669-1681 (1951).
Fendly et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor of HER2
eu Gene Product," Cancer Research 50:1550-1558 (1990).
Fernandes et al., "Biochemical and Antitumor Effects of 5,8-Dideazaisopteroylglutamate, a Unique Quinazoline Inhibitor of Thymidylate Synthase," Cancer Research 43:1117-1123 (1983).
Ferrara and Henzel, "Pituitary Follicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells," Biochemical and Biophysical Research Communications 161:851-858 (1989).
Ferris et al., "Synthesis of Quinazoline Nucleosides from Ribose and Anthranilonitrile. Application of Phase-Transfer Catalysis in Nucleoside Synthesis," J. Org. Chem. 44(2):173-178 (1979).
Fingl and Woodbury, Chapter 1, The Pharmacological Basis of Therapeutics (5th edition), eds. Goodman et al., MacMillan Publishing Co., Inc., New York, pp. 1-46 (1975).
Floege et al., "Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo," Kidney International 43:S47-S54 (1993).
Folkman and Shing, "Angiogenesis," J. Biol. Chem., 267:10931-10934 (1992).
Folkman, "Tumor Angiogenesis, Therapeutic Implications," New England J. Medicine 285:1182-1186 (1971).
Folkman, "What is the Evidence that Tumors are Angiogenesis Dependent?" Journal of the National Cancer Institute 82:4-6 (1990).
Fry et al., "A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase," Science 465:1093-1095 (1994).
Fry et al., "New insights into protein-tyrosine kinase receptor signaling complexes," Protein Science 2:1785-1797 (1993).
Giordano et al., "The c-met/HGF receptor in human tumours," European Journal of Cancer Prevention 1(Supplement 3):45-49 (1992).
Gottardis et al., "Estradiol-Stimulated Growth of MCF-7 Tumors Implanted in Athymic Mice: A Model to Study the Tumoristatic Action of Tamoxifen" J. Steroid Biochem. 30(1-6):311-314 (1988).
Harris et al., "Breast Cancer (First of Three Parts)," New England J. of Medicine 327(5):319-328 (1992).
Higashino et al., "Reactions of the Anion of Quinazoline Reissert Compound (3-Benzoyl-3,4-dihydro-4-quinazolinecarbonitrile) with Electrophiles," Chem. Pharm. Bull. 33:950-961 (1985).
Hirth et al., Serial No. 08/370,547 filed Jan. 6, 1996.
Honegger et al., "Point Mutation at the ATP Binding Site of EGF Receptor Abolishes Protein-Tyrosine Kinase Activity and Alters Cellular Routing," Cell 5:199-209 (1987).
Houck et al., "Dual Regulation of Vascular Endothelial Growth Factor Bioavilability by Genetic and Proteolytic Mechanisms," J. Biol. Chem. 267:26031-26037 (1992).
Hu et al., "Interaction of Phosphatidylinositol 3-Kinase-Associated p85 with Epidermal Growth Factor and Platelet-Derived Growth Factor Recpetors," Molecular and Cellular Biology 12(3):981-990 (1992).
Jackman, "ICI D1694, a Quinazoline Antifolate Thymidylate Synthase Inhibitor That Is a Potent Inhibitor of L1210 Tumor Cell Growth in Vitro and in Vivo: A New Agent for Clinical Study," Cancer Research 51:5579-5586 (1991).
Jellinek et al., "Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor," Biochemistry 33:10450-10456 (1994).
Jones et al., "Quinazoline Antifolates Inhibiting Thymidylate Synthase: Variation of the Amino Acid," J. Med. Chem. 29:1114-1118 (1986).
Jucker et al., "The Met/Hepatocyte Growth Factor Receptor (HGFR) Gene is Overexpressed in Some Cases of Human Leukemia and Lymphoma," Leukemia Research 18:7-16 (1994).
Kashishian and Cooper, "Phosphorylation Sites at the C-terminus of the Platelet-Derived Growth Factor Receptor Bind Phospholipase C.gamma.1," Molecular Biology of the Cell 4:49-57 (1993).
Kashishian et al., "Phosphorylation sites in the PDGF receptor with different specificities for binding GAP and P13 kinase in vivo," The EMBO Journal 11(4):1373-1382 (1992).
Kazlauskas et al., "The 64-kDa protein that associates with the platelet-derived growth factor receptor .beta. subunit via Tyr-1009 is the SH2-containing phosphotyrosine phosphatase Syp," Proc. Natl. Acad. Sci. USA 90:6939-6942 (1993).
Kendall and Thomas, "Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor," Proc. Natl. Acad. Sci. USA 90:10705-10709 (1993).
Kim et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour
McMahon Gerald
Tang Peng Cho
Kifle Bruck
Shah Mukund J.
Sugen Inc.
LandOfFree
Quinazolines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinazolines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinazolines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2007125